Pfizer Given Buy Rating at TheStreet (PFE)
Pfizer (NYSE:PFE)‘s stock had its “buy” rating reiterated by stock analysts at TheStreet in a report issued on Tuesday, AR Network reports.
The analysts wrote, “Pfizer (PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
A number of other analysts have also recently weighed in on PFE. Analysts at Ned Davis Research downgraded shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Monday. Separately, analysts at Jefferies Group upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. They now have a $38.00 price target on the stock, up previously from $33.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Wednesday, January 29th. They now have a $32.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Pfizer has a consensus rating of “Hold” and an average price target of $32.28.
Pfizer (NYSE:PFE) opened at 31.71 on Tuesday. Pfizer has a 52-week low of $26.81 and a 52-week high of $32.50. The stock has a 50-day moving average of $30.73 and a 200-day moving average of $30.03. The company has a market cap of $205.5 billion and a P/E ratio of 9.85.
Pfizer (NYSE:PFE) last announced its earnings results on Monday, January 27th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.52 by $0.04. The company had revenue of $13.56 billion for the quarter, compared to the consensus estimate of $13.35 billion. During the same quarter in the prior year, the company posted $0.47 earnings per share. The company’s quarterly revenue was down 2.4% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.27 earnings per share for the current fiscal year.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.